Pharmaceutical professional with experience in global marketing, competitive intelligence, business analysis and biotechnology research.

Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. We are focused on discovering, developing, manufacturing and commercializing targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. We work together with urgency to improve and extend the lives of people living with cancer.